Frontier Medicines vs Emulate

Side-by-side comparison of AI visibility scores, market position, and capabilities

Emulate leads in AI visibility (74 vs 36)
Frontier Medicines logo

Frontier Medicines

EmergingLife Sciences & BioTech

Precision Oncology & Undruggable Target Drug Discovery

Frontier Medicines is a precision medicine biotech targeting previously undruggable disease-causing proteins using chemoproteomics and covalent chemistry platforms; raised $350M+ in funding including a $257M Series C in 2022;

AI VisibilityBeta
Overall Score
D36
Category Rank
#83 of 198
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
33
Gemini
37

About

Frontier Medicines is a South San Francisco-based biopharmaceutical company founded in 2018 by Ulf Bhatt and Jonathan Ogg, with scientific founding involvement from leading chemoproteomics researchers. The company's core focus is developing precision medicines against proteins that have historically been considered "undruggable" — disease-causing targets where conventional drug discovery approaches have failed due to the protein's structure, chemistry, or biology. Frontier addresses this challenge through two proprietary technology platforms: the Frontier platform (chemoproteomics-based covalent chemistry for small molecule drug discovery) and the AutoTAC platform (targeted protein degradation using autophagy pathways).

Full profile
Emulate logo

Emulate

LeaderLife Sciences & BioTech

Organ-on-Chip & Drug Development Tools

Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.

AI VisibilityBeta
Overall Score
B74
Category Rank
#8 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
73
Gemini
77

About

Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#83
Category Rank
#8
86
AI Consensus
73
stable
Trend
stable
36
ChatGPT
78
33
Perplexity
73
37
Gemini
77
38
Claude
79
39
Grok
68

Key Details

Category
Precision Oncology & Undruggable Target Drug Discovery
Organ-on-Chip & Drug Development Tools
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.